Dabrafenib (GSK2118436)

Name: Dabrafenib (GSK2118436)
Brand: Selleck Chemicals
SKU: S2807
Rating: 5 (152 reviews)

For research use only.

Catalog No.S2807

152 publications

Dabrafenib (GSK2118436) Chemical Structure

Molecular Weight(MW): 519.56

Dabrafenib (GSK2118436) is a mutant BRAFV600 specific inhibitor with IC50 of 0.7 nM in cell-free assays, with 7- and 9-fold less potency against B-Raf(wt) and c-Raf, respectively.

Selleck's Dabrafenib (GSK2118436) has been cited by 152 publications

Nature, 2019, 575(7781):203-209

PubMed: 31666698 ( click the link to review the publication )

Nat Med, 2018, 24(2):203-212

PubMed: 29334371 ( click the link to review the publication )

Cell, 2018, 173(6):1413-1425

PubMed: 29754815 ( click the link to review the publication )

Cancer Discov, 2018, 8(4):417-427

PubMed: 29431697 ( click the link to review the publication )

Nature, 2017, 550(7674):133-136

PubMed: 28953887 ( click the link to review the publication )

Nature, 2017, 551(7679):247-250

PubMed: 29088702 ( click the link to review the publication )

Science, 2016, 352(6282):189-96

PubMed: 27124452 ( click the link to review the publication )

Nat Med, 2016, 22(9):1056-61

PubMed: 27500726 ( click the link to review the publication )

Cancer Cell, 2016, 12;30(3):485-498

PubMed: 27523909 ( click the link to review the publication )

Cancer Discov, 2015, 5(4):358-67

PubMed: 25673644 ( click the link to review the publication )

Cancer Discov, 2014, 4(1):69-79

PubMed: 24265152 ( click the link to review the publication )

Sci Adv, 2020, 22;6(21):eaaz8521

PubMed: 32494745 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2020, 202004707

PubMed: 32561648 ( click the link to review the publication )

Oncogene, 2020, 39(20):4132-4154

PubMed: 32238882 ( click the link to review the publication )

Cancers (Basel), 2020, 22;12(2) pii: E512

PubMed: 32098410 ( click the link to review the publication )

PLoS Pathog, 2020, 16;16(3):e1008341

PubMed: 32176725 ( click the link to review the publication )

Sci Rep, 2020, 8;10(1):7826

PubMed: 32385388 ( click the link to review the publication )

Sci Rep, 2020, 27;10(1):5557

PubMed: 32221312 ( click the link to review the publication )

J Biol Chem, 2020, 295(8):2407-2420

PubMed: 31929109 ( click the link to review the publication )

Acta Pharmacol Sin, 2020, 13

PubMed: 32404982 ( click the link to review the publication )

Front Chem, 2020, 23;8:184

PubMed: 32266211 ( click the link to review the publication )

Pathol Oncol Res, 2020, 10.1007/s12253-020-00834-y

PubMed: 32591993 ( click the link to review the publication )

Anticancer Res, 2020, 40(4):1867-1874

PubMed: 32234874 ( click the link to review the publication )

Br J Cancer, 2020, 122(6):789-800

PubMed: 31932756 ( click the link to review the publication )
Cancer Cell, 2020, 37(3):387-402

PubMed: 32142667 ( click the link to review the publication )

Mol Cell, 2019, 76(6):872-884

PubMed: 31606273 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2197

PubMed: 31097693 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5143

PubMed: 31723142 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(21):6429-6442

PubMed: 31439581 ( click the link to review the publication )

Cell Rep, 2019, 26(1):65-78

PubMed: 30605687 ( click the link to review the publication )

Cell Rep, 2019, 29(3):573-588

PubMed: 31618628 ( click the link to review the publication )

Cell Death Differ, 2019, 10.1038/s41418-019-0298-5

PubMed: 30742091 ( click the link to review the publication )

Eur J Cancer, 2019, 109:137-153

PubMed: 30721788 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):272

PubMed: 31227006 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):56

PubMed: 30728057 ( click the link to review the publication )

Cancers (Basel), 2019, 11(9)

PubMed: 31547367 ( click the link to review the publication )

Cancers (Basel), 2019, 11(9)

PubMed: 31533235 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2019, 10.1111/pcmr.12824

PubMed: 31518489 ( click the link to review the publication )

Cell Death Dis, 2019, 10(4):281

PubMed: 30911007 ( click the link to review the publication )

Acta Neuropathol Commun, 2019, 7(1):128

PubMed: 31391125 ( click the link to review the publication )

Acta Neuropathol Commun, 2019, 7(1):119

PubMed: 31345255 ( click the link to review the publication )

ACS Chem Biol, 2019, 10.1021/acschembio-00191

PubMed: 31243962 ( click the link to review the publication )

Mol Pharm, 2019, 16(9):3904-3915

PubMed: 31318566 ( click the link to review the publication )

J Virol, 2019, 10.1128/JVI.01791-19

PubMed: 31826996 ( click the link to review the publication )

Biochem Pharmacol, 2019, 169:113616

PubMed: 31445021 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1225

PubMed: 30718660 ( click the link to review the publication )

Cancer Cell Int, 2019, 19:223

PubMed: 31467489 ( click the link to review the publication )

Surgery, 2019, 10.1016/j.surg.2019.04.076

PubMed: 31585718 ( click the link to review the publication )
Acta Pharmacol Sin, 2019, 40(2):268-278

PubMed: 29777202 ( click the link to review the publication )

Metabolites, 2019, 9(11)

PubMed: 31744229 ( click the link to review the publication )

Chembiochem, 2019, 10.1002/cbic.201900266

PubMed: 31152574 ( click the link to review the publication )

PLoS One, 2019, 14(6):e0217399

PubMed: 31158244 ( click the link to review the publication )

Photodermatol Photoimmunol Photomed, 2019, 10.1111/phpp.12520

PubMed: 31618797 ( click the link to review the publication )

Reprod Domest Anim, 2019, 54(5):741-749

PubMed: 30785650 ( click the link to review the publication )

Target Oncol, 2019, 14(5):619-626

PubMed: 31502118 ( click the link to review the publication )

Sci Adv, 2019, 5(8):eaav8463

PubMed: 31453322 ( click the link to review the publication )

Mol Ther Nucleic Acids, 2019, 14:287-300

PubMed: 30654190 ( click the link to review the publication )

Ann Biomed Eng, 2019, 10.1007/s10439-019-02269-2

PubMed: 31020445 ( click the link to review the publication )

Sci Rep, 2019, 9(1):10865

PubMed: 31350469 ( click the link to review the publication )

Exp Gerontol, 2019, 126:110691

PubMed: 31421186 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(23)

PubMed: 31783660 ( click the link to review the publication )

Transl Oncol, 2019, 13(2):275-286

PubMed: 31874374 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(8):578-588

PubMed: 31015631 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(4):239-253

PubMed: 30936439 ( click the link to review the publication )

Mol Cell, 2018, 69(6):923-937

PubMed: 29547721 ( click the link to review the publication )

Mol Cell, 2018, 70(5):920-935

PubMed: 29883609 ( click the link to review the publication )

Nat Protoc, 2018, 13(12):2827-2843

PubMed: 30382243 ( click the link to review the publication )

Nat Commun, 2018, 9(1):3440

PubMed: 30143629 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2500

PubMed: 29950559 ( click the link to review the publication )

Nat Commun, 2018, 9(1):1466

PubMed: 29654229 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(5):1090-1102

PubMed: 29196297 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(14):3377-3385

PubMed: 29650750 ( click the link to review the publication )
Cancer research, 2018, 78(2):542-557

PubMed: 29180473 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(23):6066-6077

PubMed: 30061362 ( click the link to review the publication )

Breast Cancer Res, 2018, 20(1):9

PubMed: 29382358 ( click the link to review the publication )

Cell Chem Biol, 2018, 25(2):175-184

PubMed: 29249695 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(1):84-95

PubMed: 29133617 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(4):806-813

PubMed: 29167314 ( click the link to review the publication )

Mol Oncol, 2018, 12(1):74-88

PubMed: 29112787 ( click the link to review the publication )

Neoplasia, 2018, 20(5):467-477

PubMed: 29605720 ( click the link to review the publication )

Hum Mol Genet, 2018, 27(22):3974-3985

PubMed: 30137437 ( click the link to review the publication )

Oncogenesis, 2018, 7(9):67

PubMed: 30190455 ( click the link to review the publication )

Sci Rep, 2018, 8(1):9991

PubMed: 29968772 ( click the link to review the publication )

Front Pharmacol, 2018, 9:856

PubMed: 30154717 ( click the link to review the publication )

ACS Med Chem Lett, 2018, 9(12):1199-1204

PubMed: 30613326 ( click the link to review the publication )

Acta Biochim Biophys Sin (Shanghai), 2018, 50(4):355-361

PubMed: 29534162 ( click the link to review the publication )

Anticancer Res, 2018, 38(11):6195-6200

PubMed: 30396937 ( click the link to review the publication )

Oncotarget, 2018, 9(92):36503-36514

PubMed: 30559933 ( click the link to review the publication )

Cell Death Dis, 2018, 9(3):325

PubMed: 29487283 ( click the link to review the publication )

Oncotarget, 2018, 9(17):13324-13336

PubMed: 29568360 ( click the link to review the publication )

Small GTPases, 2018, 10.1080/21541248.2018.1446697

PubMed: 29634387 ( click the link to review the publication )

Sci Rep, 2018, 8(1):10724

PubMed: 30013176 ( click the link to review the publication )

NPJ Syst Biol Appl, 2018, 4:39

PubMed: 30416750 ( click the link to review the publication )

Oncoimmunology, 2018, 8(1):e1512456

PubMed: 30546949 ( click the link to review the publication )

Cell Syst, 2018, 7(2):161-179

PubMed: 30007540 ( click the link to review the publication )

Oncotarget, 2018, 9(51):29680-29697

PubMed: 30038713 ( click the link to review the publication )
Oncotarget, 2018, 9(47):28294-28308

PubMed: 29983861 ( click the link to review the publication )

Neural Regen Res, 2018, 13(2):252-256

PubMed: 29557374 ( click the link to review the publication )

Nat Commun, 2017, 8:15623

PubMed: 28585535 ( click the link to review the publication )

Nat Commun, 2017, 8(1):823

PubMed: 29018192 ( click the link to review the publication )

Cancer Res, 2017, 77(17):4684-4696

PubMed: 28652244 ( click the link to review the publication )

Cell Mol Life Sci, 2017, 74(19):3631-3645

PubMed: 28551825 ( click the link to review the publication )

Transl Lung Cancer Res, 2017, 6(5):600-610

PubMed: 29114475 ( click the link to review the publication )

Sci Rep, 2017, 7(1):15523

PubMed: 29138474 ( click the link to review the publication )

Anal Bioanal Chem, 2017, 409(15):3749-3756

PubMed: 28429064 ( click the link to review the publication )

Oncol Rep, 2017, 38(5):2741-2751

PubMed: 29048639 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 489(1):14-20

PubMed: 28536078 ( click the link to review the publication )

Oncotarget, 2017, 8(40):68208-68220

PubMed: 28978109 ( click the link to review the publication )

Oncotarget, 2017, 8(64):107977-107990

PubMed: 29296217 ( click the link to review the publication )

Biochim Biophys Acta Gen Subj, 2017, 1861(11 Pt B):2980-2992

PubMed: 28408301 ( click the link to review the publication )

Cell Death Differ, 2017, 24(1):83-97

PubMed: 27834956 ( click the link to review the publication )

Genome Res, 2017, 27(4):613-625

PubMed: 28179366 ( click the link to review the publication )

Oncogene, 2017, 36(27):3842-3851

PubMed: 28263969 ( click the link to review the publication )

Elife, 2017, 6

PubMed: 28350298 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(29):E5930-E5939

PubMed: 28684402 ( click the link to review the publication )

Int J Mol Sci, 2017, 18(10)

PubMed: 29064427 ( click the link to review the publication )

Oncotarget, 2017, 8(52):90262-90277

PubMed: 29163826 ( click the link to review the publication )

Oncotarget, 2017, 9(9):8206-8222

PubMed: 29492189 ( click the link to review the publication )

Blood Adv, 2017, 30;1(24):2147-2160

PubMed: 29296862 ( click the link to review the publication )

Nat Commun, 2016, 7:10274

PubMed: 26817517 ( click the link to review the publication )
Autophagy, 2016, 12(10):1776-1790

PubMed: 27464255 ( click the link to review the publication )

Leukemia, 2016, 30(4):937-46

PubMed: 26582644 ( click the link to review the publication )

Mol Cancer Ther, 2016, 10.1158/1535-7163.MCT-15-0375

PubMed: 27196768 ( click the link to review the publication )

J Biol Chem, 2016, 291(34):17804-15

PubMed: 27226552 ( click the link to review the publication )

Cancer Biol Ther, 2016, 17(7):778-84

PubMed: 26810603 ( click the link to review the publication )

PLoS One, 2016, 11(3):e0152104

PubMed: 27015094 ( click the link to review the publication )

Oncotarget, 2016, 8(35):58021-58036

PubMed: 28938534 ( click the link to review the publication )

Oncotarget, 2016, 7(21):30453-60

PubMed: 27028853 ( click the link to review the publication )

Sci Rep, 2016, 6:23713

PubMed: 27025703 ( click the link to review the publication )

Elife, 2016, 5

PubMed: 27557444 ( click the link to review the publication )

Oncotarget, 2016, 7(46):75839-75853

PubMed: 27713119 ( click the link to review the publication )

Oncotarget, 2016, 7(12):15065-92

PubMed: 26918341 ( click the link to review the publication )

Cell Res, 2015, 10.1038/cr.2015.56

PubMed: 25952668 ( click the link to review the publication )

Mol Ther, 2015, 23(5):931-942

PubMed: 25619724 ( click the link to review the publication )

J Invest Dermatol, 2015, 135(8):2021-2030

PubMed: 25748555 ( click the link to review the publication )

Antimicrob Agents Chemother, 2015, 59(2):1088-99

PubMed: 25487801 ( click the link to review the publication )

J Immunother, 2015, 38(1):12-23

PubMed: 25415284 ( click the link to review the publication )

Eur J Pharmacol, 2015, 762:283-92

PubMed: 26048310 ( click the link to review the publication )

PLoS One, 2015, 10(12):e0143847

PubMed: 26630652 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0123410

PubMed: 25844720 ( click the link to review the publication )

Cancer Res, 2015, 75(1):216-29

PubMed: 25381152 ( click the link to review the publication )

Drug Metab Dispos, 2015, 43(12):1934-7

PubMed: 26443648 ( click the link to review the publication )

Oncotarget, 2015, 6(38):40535-56

PubMed: 26497853 ( click the link to review the publication )

Cancer Immunol Res, 2015, 3(6):602-9

PubMed: 25795007 ( click the link to review the publication )
Oncotarget, 2015, 6(31):31792-804

PubMed: 26397139 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(12):2700-11

PubMed: 26351322 ( click the link to review the publication )

J Clin Invest, 2014, 124(3):1406-17

PubMed: 24569374 ( click the link to review the publication )

J Clin Invest, 2014, 124(11):5074-84

PubMed: 25329694 ( click the link to review the publication )

Cancer Res, 2014, 10.1158/0008-5472.CAN-14-1392

PubMed: 25297634 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1278

PubMed: 24901049 ( click the link to review the publication )

Transl Res, 2014, 164(5):411-23

PubMed: 25016932 ( click the link to review the publication )

The University of Texas, 2014, Lizee S

PubMed: ( click the link to review the publication )

Purity & Quality Control

Choose Selective Raf Inhibitors

Biological Activity

Description

Dabrafenib (GSK2118436) is a mutant BRAFV600 specific inhibitor with IC50 of 0.7 nM in cell-free assays, with 7- and 9-fold less potency against B-Raf(wt) and c-Raf, respectively.

Targets

B-Raf (V600E) ^[3] (Cell-free assay)	B-Raf ^[3] (Cell-free assay)	C-Raf ^[3] (Cell-free assay)
0.7 nM	5.2 nM	6.3 nM

In vitro

Dabrafenib is selective for Raf kinase, with 400 fold selectivity towards B-Raf over 91% of the other kinases tested. Dabrafenib inhibits B-Raf^V600E kinase, leading to decreased ERK phosphorylation and inhibition of cell proliferationby an initial arrest in the G1 phase of the cell cycle in cancer cells that specifically encode the mutation for B-Raf^V600E. ^[1]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
	NIrVWoJMcW6jc3WgRZN{[Xl?				MWTJcohq[mm2aX;uJI9nKE5vdHXycYlv[WxiSHnzJJRi\2enZDDCMXJi\iCYNkCwSUBufXSjboSg[ZhxemW\|c3XkJIlvKGKjY4Xsc5ZqenW\|IHnu[oVkfGWmIHnud4VkfCClZXzsd{Bkdy2neIDy[ZN{cW6pIFPER\|M4KGG\|c3Xzd4VlKGG\|IHTlZ5Jm[XOnIHnuJIJqd3SrbonsZZRm\C2PRVugdJJwfGWrbjDwbI9{eGixconsZZRqd25iYomgRYxxcGGVY4Ll[Y4h[XO\|YYmge4l1cCCLQ{WwJI9nKDBwMECwO{DPxE1?	NWPVbJZsOjR7MEC2O\|M>
SK-MEL-28	Mn3mT4lv[XOnIFHzd4F6		MYSxJIg>		MXLJcohq[mm2aX;uJI9nKEJvUnHmJHY3ODCHIH31eIFvfCCrbjDoeY1idiCVSz3NSWwuOjhiY3XscJMh[XO\|ZYPz[YQh[XNiZHXjdoVie2ViaX6gSXJMKHCqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFQh\|ryP	NUfUSo5uOjR7MEC2O\|M>
HepG2	NFvMNm9McW6jc3WgRZN{[Xl?				M1;RXGlvcGmkaYTpc44hd2ZiQj3SZYYhXjZyMFWgcZV1[W62IHnuJIh2dWGwIFjldGczKGOnbHzzJIF{e2W\|c3XkJIF{KGSnY4LlZZNmKGmwIFXST{BxcG:\|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDBwMEC0JO69VQ>?	NV;iOlZ6OjR7MEC2O\|M>
COLO205	NFfRemJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M33qN2lvcGmkaYTpc44hd2ZiaIXtZY4hS0:OT{KwOUBk\WyuIIDyc4xq\mW{YYTpc44hf2m2aDDJR\|UxKG:oIECuNFA4KM7:TR?=	MnPtNlQ6ODB4N{O=
HepG2	MXLGeY5kfGmxbjDBd5NigQ>?		MkP0OFUhdWmw	NFLwTVNFVVOR	NFzVcWxKdmirYnn0bY9vKG:oIFHsb\|UhcW5iVFfGMYJmfGFvc4TpcZVt[XSnZDDoeY1idiCKZYDHNkBk\WyuczDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiCVbXHkNkBxcG:\|cHjvdplt[XSrb36geJJm[XSnZDDmc5IhPDVibXnud{BxemmxcjD0c{BVT0ZvYnX0ZUB{fGmvdXzheIlwdiCvZXHzeZJm\CCjZoTldkA3OCCvaX7zJIJ6KG:meYPz[Zkh[myxdDDzZ4FvdmW{IHHuZYx6e2m\|IIfpeIghUUN3MDDv[kA{NjdizszN	NWHtZXgyOjR7MEC2O\|M>
HFF	Mnr3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHTi[WEyOCEQvF2=	NHXHe4k4OiCq	NHjVV4ZFVVOR	M3vVNWlvcGmkaYTpc44hd2ZicILvcIln\XKjdHnvckBw\iCqdX3hckBJTkZiY3XscJMhcGG{Yn;ybY5oKHerbHSgeJlx\SCELWLh[kB4cXSqIFnDOVAhd2ZiMzFOwG0>	MoPiNlM5PDRyM{i=
SK-MEL-28	MlK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXK5UIpDOTBizszN	NIrrWIQ4OiCq	M1vu[GROW09?	NHy1WlJKdmirYnn0bY9vKG:oIFKtVoFnKFZ4MEDFJI12fGGwdD3kdol3\W5iU1utUWVNNTJ6IHPlcIwheHKxbHnm[ZJifGmxbjD3bZRpKEmFNUCgc4YhOC5yNEOg{txO	NXrHcXZzOjN6NESwN\|g>
A375P-F11	NELHWW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUj3doY6OTBizszN	MWS3NkBp	MXrEUXNQ	MV3Jcohq[mm2aX;uJI9nKEJvUnHmJHY3ODCHIH31eIFvfC2mcnn2[Y4hSTN5NWCtSlEyKGOnbHygdJJwdGmoZYLheIlwdiC5aYToJGlEPTBib3[gNE4xPzFizszN	M2XyTlI{QDR2MEO4
MALME-3M	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2XTflExKM7:TR?=	NWDjd3p5PzJiaB?=	NUTLeFJrTE2VTx?=	M2jtcGlEPTB;MTDuUS=>	MkjLNlM5PDRyM{i=
UACC-62	NEXmdoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVG1NHZEOTBizszN	NUjIUYxUPzJiaB?=	NI\kXJlFVVOR	NFvGeVVKSzVyPUGgcm0>	M33QclI{QDR2MEO4
C32TG	NFfqU4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUnzOWl6OTBizszN	MnnyO\|IhcA>?	NEO3[GFFVVOR	NVLDdpZNUUN3ME2xJI5O	NF7jRpozOzh2NECzPC=>
SK-MEL-1	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF;kOVEyOCEQvF2=	NU\XN3pIPzJiaB?=	NH\IXJZFVVOR	NUPqWZNRUUN3ME2yJI5O	NEGyWVIzOzh2NECzPC=>
M14	NILXeI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1HBSlExKM7:TR?=	NWnyR4I4PzJiaB?=	MWfEUXNQ	MlTtTWM2OD1{IH7N	NWPtdZB4OjN6NESwN\|g>
SK-MEL-28	NYLuc2tFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVKxNEDPxE1?	NUjTcpk2PzJiaB?=	MWTEUXNQ	MUXJR\|UxRTNibl2=	NYSwfphCOjN6NESwN\|g>
A375	M{\yU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3HIcFExKM7:TR?=	NVLOZog3PzJiaB?=	MUHEUXNQ	NVvUV4s3UUN3ME20JI5O	Mm\ZNlM5PDRyM{i=
DU-4475	NXXXUnJST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkOxNVAh\|ryP	NYLH[Jk3PzJiaB?=	M4XUSGROW09?	NFHu[FFKSzVyPUWgcm0>	MVmyN\|g1PDB\|OB?=
UACC-257	M165emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUnleolLOTBizszN	MUi3NkBp	MWrEUXNQ	NHTPN5pKSzVyPU[gcm0>	NXj1T2JTOjN6NESwN\|g>
Colo 205	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1LJVlExKM7:TR?=	MX[3NkBp	MofDSG1UVw>?	NIfUNpFKSzVyPUegcm0>	NEDXbWszOzh2NECzPC=>
SK-MEL-3	NYezPINlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH3sZ\|IyOCEQvF2=	M4D6SFczKGh?	NXG5XXE4TE2VTx?=	NF\ISVdKSzVyPUegcm0>	NXPvOW1HOjN6NESwN\|g>
SH-4	M37RPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MojGNVAh\|ryP	NFzVTGQ4OiCq	M4rVdmROW09?	NGnFc3BKSzVyPUigcm0>	NHXQdFIzOzh2NECzPC=>
A101D	NELqSnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlvyNVAh\|ryP	NVXWcZlOPzJiaB?=	NVGwd5I3TE2VTx?=	NYrhfHpnUUN3ME25JI5O	NX;NNI83OjN6NESwN\|g>
ES-2	NIXhZWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWPVXVVtOTBizszN	NIDrPW84OiCq	MnLzSG1UVw>?	Mn3XTWM2OD13MzDuUS=>	MYWyN\|g1PDB\|OB?=
HT-29	NWfzN5ZpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV:xNEDPxE1?	MXS3NkBp	MYfEUXNQ	MYfJR\|UxRTZ4IH7N	MUmyN\|g1PDB\|OB?=
SW1417	NV7WeVc4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXqxNEDPxE1?	NUGxNYtRPzJiaB?=	NF\MfIFFVVOR	NESxU25KSzVyPUG1PEBvVQ>?	MUGyN\|g1PDB\|OB?=
SW872	MnLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV7q[oFpOTBizszN	M1fXOVczKGh?	M3;JN2ROW09?	MYLJR\|UxRTN5NzDuUS=>	NGLoNHEzOzh2NECzPC=>
RKO	M13tfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmrENVAh\|ryP	MkHQO\|IhcA>?	NXL4Z\|FZTE2VTx?=	M{mycmlEPTB;Mj61NlIh\|ryP	MmPJNlM5PDRyM{i=
A673	NEL0fXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYmxNEDPxE1?	MlLrO\|IhcA>?	MXLEUXNQ	NIPoc\|ZKSzVyPUGwJO69VQ>?	MnrwNlM5PDRyM{i=
GCT	NIDZNI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NET3[oUyOCEQvF2=	M{LvcVczKGh?	M3S4VmROW09?	M{j1U2lEPTB;MUCg{txO	M3PLZ\|I{QDR2MEO4
WM-115	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NI\4VJIyOCEQvF2=	M3LHXVczKGh?	MoXVSG1UVw>?	NF\GfIZKSzVyPUWgcm0>	NWnJOXVXOjN6NESwN\|g>
YUMAC	MoTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYjsN\|AzOTBizszN	MXK3NkBp	M{LZPWROW09?	MoP3TWM2OD13IH7N	Mk\lNlM5PDRyM{i=
OV-90	MmHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M33aSFExKM7:TR?=	M4PmUlczKGh?	Mlf6SG1UVw>?	NFW3OY1KSzVyPUK5JI5O	NFHvc3AzOzh2NECzPC=>
NCI-H508	NIDneItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVixNEDPxE1?	MnnTO\|IhcA>?	NFvxUHJFVVOR	MojDTWM2OD1zMDFOwG0>	MXOyN\|g1PDB\|OB?=
MDA-MB-231	NVO2NmdXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVLGTGx1OTBizszN	NIfGPWQ4OiCq	NFH2c5FFVVOR	MlLxTWM2OD1zMDFOwG0>	M13BTFI{QDR2MEO4
SW756	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3zSN\|ExKM7:TR?=	M3zqN\|czKGh?	MVzEUXNQ	M2LPV2lEPTB;MUCg{txO	M3PrWVI{QDR2MEO4
SW-837	NYDVZ\|V3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NInOcIYyOCEQvF2=	MVy3NkBp	MlrFSG1UVw>?	MkDRTWM2OD1zMDFOwG0>	M{LwclI{QDR2MEO4
UMUC-3	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF;1[FYyOCEQvF2=	NF3abW44OiCq	NIHsfnBFVVOR	NYP0VVVKUUN3ME2xNEDPxE1?	M2T5VFI{QDR2MEO4
LS-174T	NXXNflQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{TieFExKM7:TR?=	Ml7UO\|IhcA>?	Ml75SG1UVw>?	NFK1cG1KSzVyPUGwJO69VQ>?	M{m5UlI{QDR2MEO4
A549	NF20UmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mnr1NVAh\|ryP	NHnEcI84OiCq	MYHEUXNQ	NFLFcXZKSzVyPUGwJO69VQ>?	M1vrWFI{QDR2MEO4
SHP-77	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHXmOWMyOCEQvF2=	M{nCclczKGh?	Mn;FSG1UVw>?	M1q5OWlEPTB;MUCg{txO	MYCyN\|g1PDB\|OB?=
SW480	NGrlVFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MW[xNEDPxE1?	MljHO\|IhcA>?	MlTFSG1UVw>?	NYiwVZh[UUN3ME2xNEDPxE1?	M{PoUVI{QDR2MEO4
DLD-1	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3v3XlExKM7:TR?=	MnvOO\|IhcA>?	MVPEUXNQ	MVXJR\|UxRTFyIN88US=>	MnXlNlM5PDRyM{i=
HCT-116	NV;Yem1xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVSxNEDPxE1?	MXi3NkBp	M3TQVGROW09?	M4TaNWlEPTB;MUCg{txO	M3uyTFI{QDR2MEO4
NCI-H747	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mm\lNVAh\|ryP	MorVO\|IhcA>?	MkPTSG1UVw>?	M2\qXmlEPTB;MUCg{txO	NV7r[ItkOjN6NESwN\|g>
T-84	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVqxNEDPxE1?	MmnzO\|IhcA>?	MXjEUXNQ	MWDJR\|UxRTFyIN88US=>	MUWyN\|g1PDB\|OB?=
NCI-H460	MmXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIHGO\|IyOCEQvF2=	MkjjO\|IhcA>?	NFzRRWhFVVOR	NWrRXocyUUN3ME2xNEDPxE1?	M{G0c\|I{QDR2MEO4
Calu-6	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFfjeYsyOCEQvF2=	MUi3NkBp	NG\OSFdFVVOR	MVnJR\|UxRTFyIN88US=>	Ml7TNlM5PDRyM{i=
HCC-2998	MoHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWGxNEDPxE1?	NXrl[YsxPzJiaB?=	M{\xO2ROW09?	MV7JR\|UxRTFyIN88US=>	NITKOZEzOzh2NECzPC=>
LS1034	MkjES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYXOR2hWOTBizszN	NY\YeXVFPzJiaB?=	M{PDOGROW09?	NFzLZ4RKSzVyPUGwJO69VQ>?	Ml;TNlM5PDRyM{i=
CHP-212	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFr6NHUyOCEQvF2=	NXPLcWN3PzJiaB?=	NUHaVmRjTE2VTx?=	NYXw[IdsUUN3ME2xNEDPxE1?	NIGzRpMzOzh2NECzPC=>
SK-N-AS	Mn;SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGW3S\|EyOCEQvF2=	NFzIPJY4OiCq	M{nwcmROW09?	MUfJR\|UxRTFyIN88US=>	NIC1e3czOzh2NECzPC=>
BFTC-905	NVXjW25ET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXmxNEDPxE1?	Mn73O\|IhcA>?	NVnz[lZ6TE2VTx?=	MlS4TWM2OD1zMDFOwG0>	NVvF[lhKOjN6NESwN\|g>
HuT78	NVztdlRoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUexNEDPxE1?	NEnnWmk4OiCq	M{Wwc2ROW09?	M{LLS2lEPTB;NUKgcm0>	M{K0TlI{QDR2MEO4
RPMI-8226	M4fFb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYTvU\|lSOTBizszN	MnezO\|IhcA>?	NWrmbpdqTE2VTx?=	MX\JR\|UxRTJ4MzDuUS=>	NXL5Olc3OjN6NESwN\|g>
BC-3	NEnoOFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mmi2NVAh\|ryP	MWe3NkBp	MWjEUXNQ	M3jvXWlEPTB;Mke3JI5O	MlzENlM5PDRyM{i=
ACHN	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnzMNVAh\|ryP	MkLZO\|IhcA>?	NVe5dY9VTE2VTx?=	MUTJR\|UxRTJ7NDDuUS=>	NX\jfmdVOjN6NESwN\|g>
JRT3-T35	M2X3Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NE\a[WQyOCEQvF2=	NVvXSVV1PzJiaB?=	MWXEUXNQ	M1e5fWlEPTB;Mkm1JI5O	NVP6WpN2OjN6NESwN\|g>
SK-MES-1	M2myemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYGxNEDPxE1?	M1rFTVczKGh?	M4r4OmROW09?	MmTRTWM2OD1\|Mkmgcm0>	NITlWnkzOzh2NECzPC=>
CESS	MoPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkLaNVAh\|ryP	NGnBWlk4OiCq	M3jiTGROW09?	MoH2TWM2OD12OUegcm0>	NFG0U4szOzh2NECzPC=>
H4	M1rSXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1vQclExKM7:TR?=	NVfnbYNmPzJiaB?=	M{HmemROW09?	MkToTWM2OD14MUmgcm0>	Mn;QNlM5PDRyM{i=
BC-1	NWXGUY1xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUSxNEDPxE1?	M17hPVczKGh?	MnuzSG1UVw>?	NWOydFNyUUN3ME23NFQhdk1?	NXvPeI5vOjN6NESwN\|g>
DB	NWHFW24zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmTYNVAh\|ryP	NY\ZTYZvPzJiaB?=	M1z3NGROW09?	M3y4[mlEPTB;OEezJI5O	MnjINlM5PDRyM{i=
RPMI-6666	NV7JOWlLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX2xNEDPxE1?	Mo\6O\|IhcA>?	M2X1dGROW09?	MV3JR\|UxRTl{ODDuUS=>	NYf0ZoFmOjN6NESwN\|g>
MC/CAR	Moj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3yzVVExKM7:TR?=	NV3Re2E1PzJiaB?=	MWPEUXNQ	NWS3eWNbUUN3ME2xMlAxOiEQvF2=	MUWyN\|g1PDB\|OB?=
SNU-1	NIHvSWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX\EdYdNOTBizszN	MnruO\|IhcA>?	MVPEUXNQ	MnvYTWM2OD1zLkWwNUDPxE1?	MUGyN\|g1PDB\|OB?=
CEM/C1	M4Liemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGD2PIwyOCEQvF2=	M4LHclczKGh?	NGjuWXBFVVOR	NV3P[msxUUN3ME2xMlc4OyEQvF2=	NHXZUoYzOzh2NECzPC=>
GDM-1	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkDsNVAh\|ryP	M2nHZlczKGh?	MnLDSG1UVw>?	M4DBbWlEPTB;MT65PVch\|ryP	NX7GN4EzOjN6NESwN\|g>
HT-1080	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4HE[VExKM7:TR?=	M4TTdlczKGh?	NIjlbYtFVVOR	NWDuWHRpUUN3ME2yMlAxPCEQvF2=	M{Hke\|I{QDR2MEO4
HL-60	NF;VSHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn3VNVAh\|ryP	MnXwO\|IhcA>?	NYm2T2V3TE2VTx?=	NV7m[\|RPUUN3ME2yMlE4QCEQvF2=	NYTyU3hxOjN6NESwN\|g>
C3A	NXrhbZNVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHTKcVAyOCEQvF2=	MkO4O\|IhcA>?	MkfVSG1UVw>?	NF75e4tKSzVyPUWuOFE1KM7:TR?=	MYSyN\|g1PDB\|OB?=
MES-SA	MknDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUixNEDPxE1?	MknCO\|IhcA>?	MoDpSG1UVw>?	M2HpXWlEPTB;Nj65PFkh\|ryP	M3e2SlI{QDR2MEO4
22Rv1	NHzGRZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXOxNEDPxE1?	NHy0cnM4OiCq	MmrVSG1UVw>?	NV3wPXBHUUN3ME2xNEDPxE1?	NYnBN3FuOjN6NESwN\|g>
647-V	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnXvNVAh\|ryP	NFLFb5U4OiCq	NXT3dnlrTE2VTx?=	M4rJUWlEPTB;MUCg{txO	MYCyN\|g1PDB\|OB?=
786-O	NV3zOo01T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3i5NFExKM7:TR?=	NYe4cnFsPzJiaB?=	NYf0d2NsTE2VTx?=	MnXYTWM2OD1zMDFOwG0>	M{fPZ\|I{QDR2MEO4
A172	M1L1[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1fVWlExKM7:TR?=	MYe3NkBp	MmDpSG1UVw>?	MWrJR\|UxRTFyIN88US=>	MljBNlM5PDRyM{i=
A204	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHrqbW0yOCEQvF2=	MVW3NkBp	NWfENodvTE2VTx?=	NWTWPYZuUUN3ME2xNEDPxE1?	NFrXcGgzOzh2NECzPC=>
A427	NFXJV29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NITrfXEyOCEQvF2=	NUDiXVA4PzJiaB?=	MljkSG1UVw>?	M2T6OGlEPTB;MUCg{txO	NImwNVAzOzh2NECzPC=>
A431	NUXaPHZqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHnSWXoyOCEQvF2=	NVrKXG1jPzJiaB?=	NVnWV5c1TE2VTx?=	M13zPGlEPTB;MUCg{txO	NGnnbVAzOzh2NECzPC=>
A2780	M3;SOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYjsNpM{OTBizszN	M4DOUlczKGh?	M3LyXmROW09?	NIPJfZNKSzVyPUGwJO69VQ>?	Mn3aNlM5PDRyM{i=
ARH-77	NUm2eoc4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4nJVVExKM7:TR?=	M1;uTVczKGh?	NWrYNHVwTE2VTx?=	M3;QNGlEPTB;MUCg{txO	M336SVI{QDR2MEO4
Be(2)C	NHvQU3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4DzUlExKM7:TR?=	MoHsO\|IhcA>?	NV\4U5FLTE2VTx?=	Mm\YTWM2OD1zMDFOwG0>	NYS0NXd2OjN6NESwN\|g>
BT-20	M3H3UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUC4[5dlOTBizszN	NH6xTpI4OiCq	NUC5[YR4TE2VTx?=	MmLqTWM2OD1zMDFOwG0>	NVyzSXczOjN6NESwN\|g>
BxPc3	M3K4dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF\yVoQyOCEQvF2=	NH:2TXM4OiCq	NFnTdJlFVVOR	NIrhR4hKSzVyPUGwJO69VQ>?	M2S4PFI{QDR2MEO4
C-4 I	MlLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWOxNEDPxE1?	M3zNfFczKGh?	MkXjSG1UVw>?	MnPETWM2OD1zMDFOwG0>	MVGyN\|g1PDB\|OB?=
C33A	NHjmVmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1;YcVExKM7:TR?=	NVH0WWpyPzJiaB?=	NVjycnJ{TE2VTx?=	M{XwcGlEPTB;MUCg{txO	NVfi[2FSOjN6NESwN\|g>
CAL-27	NHzQd\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVHUb2xKOTBizszN	M4fvUFczKGh?	MY\EUXNQ	NYPFWZBMUUN3ME2xNEDPxE1?	NFn3OIMzOzh2NECzPC=>
CAL-62	NUfxfJRpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIXGdmsyOCEQvF2=	NVSxO4N[PzJiaB?=	M3nKcmROW09?	NFrJUllKSzVyPUGwJO69VQ>?	MXOyN\|g1PDB\|OB?=
Calu-3	MoLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVWxNEDPxE1?	MnfrO\|IhcA>?	MkXxSG1UVw>?	MYLJR\|UxRTFyIN88US=>	M1q4T\|I{QDR2MEO4
CaOV3	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGDQNHUyOCEQvF2=	MojJO\|IhcA>?	M3;lSmROW09?	M4WyW2lEPTB;MUCg{txO	MXSyN\|g1PDB\|OB?=
CGTHW1	NIeze\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX\WNpltOTBizszN	MnTnO\|IhcA>?	M{XDdWROW09?	NV7pOYdGUUN3ME2xNEDPxE1?	NVzWeHF2OjN6NESwN\|g>
CHL-1	NYLEV2VHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUexNEDPxE1?	M3j0c\|czKGh?	M2DpXWROW09?	MkPKTWM2OD1zMDFOwG0>	NWfKV2dpOjN6NESwN\|g>
Colo320DM	NH;6TWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVSxNEDPxE1?	MWK3NkBp	NITvS2pFVVOR	NEfUVG5KSzVyPUGwJO69VQ>?	NX7Yb\|dvOjN6NESwN\|g>
Colo704	NX3kWlNVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlL1NVAh\|ryP	MXW3NkBp	M2LQSWROW09?	NX7CV2RpUUN3ME2xNEDPxE1?	NXrJc2t[OjN6NESwN\|g>
COR-L23	M{TWZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGXoUpoyOCEQvF2=	NFq1WFI4OiCq	NHr1eYFFVVOR	NEfBWmpKSzVyPUGwJO69VQ>?	MkDVNlM5PDRyM{i=
CRO-AP2	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFvsTFEyOCEQvF2=	NXHXW2drPzJiaB?=	MXTEUXNQ	NXe5TWdzUUN3ME2xNEDPxE1?	MY[yN\|g1PDB\|OB?=
Daudi	MlzsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWP3Vo1VOTBizszN	NH\1fVk4OiCq	MVrEUXNQ	M3G1SmlEPTB;MUCg{txO	NGXaflUzOzh2NECzPC=>
DOTC 24510	NF\tZ49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn\WNVAh\|ryP	MkXOO\|IhcA>?	M1LndmROW09?	MXTJR\|UxRTFyIN88US=>	Mn23NlM5PDRyM{i=
DU-145	NIWxWGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWKxNEDPxE1?	MXy3NkBp	MWXEUXNQ	MVXJR\|UxRTFyIN88US=>	NGrmfFIzOzh2NECzPC=>
EB-3	NIe1VIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWGxNEDPxE1?	MXu3NkBp	M2XueGROW09?	NGq4TmpKSzVyPUGwJO69VQ>?	NYm5UZAzOjN6NESwN\|g>
EFM-19	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV6xNEDPxE1?	Mn;QO\|IhcA>?	NHK5bWlFVVOR	MWHJR\|UxRTFyIN88US=>	M{j0fVI{QDR2MEO4
EKVX	M1\Ic2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoKxNVAh\|ryP	Mkm2O\|IhcA>?	MVPEUXNQ	NV7zPYw2UUN3ME2xNEDPxE1?	MlnwNlM5PDRyM{i=
FaDu	MnzmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHHSSoIyOCEQvF2=	MVe3NkBp	MorrSG1UVw>?	MXnJR\|UxRTFyIN88US=>	MkHXNlM5PDRyM{i=
G401	NXX4[3ZET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4PxNlExKM7:TR?=	MV63NkBp	M4DxWmROW09?	M2\3R2lEPTB;MUCg{txO	MknxNlM5PDRyM{i=
HCC-70	M4izUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWWxNEDPxE1?	NXvPUVJ2PzJiaB?=	M2jKcWROW09?	M{nMbmlEPTB;MUCg{txO	NGnBU3AzOzh2NECzPC=>
HCC-1954	NF;nW\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnjZNVAh\|ryP	MUW3NkBp	NXrRV\|VUTE2VTx?=	MUfJR\|UxRTFyIN88US=>	MXmyN\|g1PDB\|OB?=
Hela	NITjd4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4DsWFExKM7:TR?=	M3\ZVlczKGh?	M1;X[WROW09?	M{SxdWlEPTB;MUCg{txO	NUDCdoR6OjN6NESwN\|g>
Hep3B	NULC[mRQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mo\4NVAh\|ryP	NV7udmo5PzJiaB?=	M364cWROW09?	NEXjUnVKSzVyPUGwJO69VQ>?	NYm4PWdVOjN6NESwN\|g>
HMCB	NHjzToRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFzoXooyOCEQvF2=	NHnaVlU4OiCq	MX\EUXNQ	NVzr[YJ2UUN3ME2xNEDPxE1?	NH;OZY0zOzh2NECzPC=>
HN5	NYLnOlRnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3uxTVExKM7:TR?=	M3TP[VczKGh?	NHfzSoRFVVOR	NVjV[5ZkUUN3ME2xNEDPxE1?	MUeyN\|g1PDB\|OB?=
HOS	M3TrSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M122XVExKM7:TR?=	M3W1TFczKGh?	MljMSG1UVw>?	Mn;kTWM2OD1zMDFOwG0>	Mmr0NlM5PDRyM{i=
HPAF-II	MkXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2TOe\|ExKM7:TR?=	MlLUO\|IhcA>?	NUXzSnFSTE2VTx?=	MY\JR\|UxRTFyIN88US=>	NFf3N48zOzh2NECzPC=>
Hs746.T	MnLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4nsclExKM7:TR?=	NIjNN2c4OiCq	MlPsSG1UVw>?	NXvLZVJlUUN3ME2xNEDPxE1?	NGPHdmszOzh2NECzPC=>
HT	NU[zfWVkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnHCNVAh\|ryP	MlPsO\|IhcA>?	M{T4WWROW09?	MoDNTWM2OD1zMDFOwG0>	NXOzbVg1OjN6NESwN\|g>
HT-3	MkjMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYmxNEDPxE1?	NUW5b3ZEPzJiaB?=	NUHVR2JuTE2VTx?=	NY[2cmJsUUN3ME2xNEDPxE1?	MUeyN\|g1PDB\|OB?=
HuNS-1	Ml7yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIfkUIgyOCEQvF2=	M37HeFczKGh?	M4qzemROW09?	MYnJR\|UxRTFyIN88US=>	NIDPTIgzOzh2NECzPC=>
IGROV1	NXq5V3dZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGDufFUyOCEQvF2=	MVy3NkBp	NYPtSWR[TE2VTx?=	M3;JVGlEPTB;MUCg{txO	NXzRZlBxOjN6NESwN\|g>
J82	M1O0NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFrwc2wyOCEQvF2=	M{\wXFczKGh?	NYjGT2ppTE2VTx?=	NXe0UG17UUN3ME2xNEDPxE1?	NXy0VXl7OjN6NESwN\|g>
JM1	NIXYV5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUWxNEDPxE1?	MUi3NkBp	MX7EUXNQ	NE\I[ZVKSzVyPUGwJO69VQ>?	Ml3INlM5PDRyM{i=
Kato III	MlPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUmxNEDPxE1?	MX63NkBp	NFGxWYRFVVOR	NIDEXplKSzVyPUGwJO69VQ>?	M2C2R\|I{QDR2MEO4
KHOS-240S	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVKxNEDPxE1?	MlO3O\|IhcA>?	NYK0NXU2TE2VTx?=	M1TKZmlEPTB;MUCg{txO	M1n4[VI{QDR2MEO4
KM-12	Mo\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXmxNEDPxE1?	NY\rVVNOPzJiaB?=	MXrEUXNQ	M4mzV2lEPTB;MUCg{txO	MkTDNlM5PDRyM{i=
KPL-1	MoO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXuxNEDPxE1?	NUi2d3Z6PzJiaB?=	NEXORYRFVVOR	NIG5VmlKSzVyPUGwJO69VQ>?	NVXFcYQ5OjN6NESwN\|g>
KYSE-30	NGe3PHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHnSTJMyOCEQvF2=	NHWyWno4OiCq	NF:0dYRFVVOR	MVfJR\|UxRTFyIN88US=>	NX3oRng3OjN6NESwN\|g>
LNCaP	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUWxNEDPxE1?	MXm3NkBp	M{KyT2ROW09?	M3fFVmlEPTB;MUCg{txO	MWiyN\|g1PDB\|OB?=
MCF-7	MnvLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX:xNEDPxE1?	NWnGcVREPzJiaB?=	MXzEUXNQ	MkDyTWM2OD1zMDFOwG0>	MlPINlM5PDRyM{i=
MC-IXC	Ml75S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3iwdlExKM7:TR?=	M1;XUFczKGh?	M2jNfWROW09?	NYnqUYZZUUN3ME2xNEDPxE1?	M4rDSFI{QDR2MEO4
MDA-MB-175 VII	M{Swb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWribppkOTBizszN	MnLqO\|IhcA>?	MUPEUXNQ	M{PB[mlEPTB;MUCg{txO	MXmyN\|g1PDB\|OB?=
MDA-MB-468	MnmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnjINVAh\|ryP	M1THUVczKGh?	M1mwZmROW09?	M4HNc2lEPTB;MUCg{txO	MlWwNlM5PDRyM{i=
MiaPaCa	NFPpWVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4KydVExKM7:TR?=	MVe3NkBp	NVvZOJk1TE2VTx?=	NIn3XYZKSzVyPUGwJO69VQ>?	NFHycmYzOzh2NECzPC=>
Molt-4	MnLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFrwfHMyOCEQvF2=	MUC3NkBp	MkDzSG1UVw>?	M3vLSGlEPTB;MUCg{txO	NXXiPY9VOjN6NESwN\|g>
NCI-ADR/RES	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlfXNVAh\|ryP	M1TVNlczKGh?	M{LzSGROW09?	MV7JR\|UxRTFyIN88US=>	NX\ESWlDOjN6NESwN\|g>
NCI-H69	MkPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4i1b\|ExKM7:TR?=	M4TIT\|czKGh?	NEOwTFJFVVOR	M2fsWmlEPTB;MUCg{txO	M17kblI{QDR2MEO4
NCI-H82	Mmf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWCxNEDPxE1?	MWq3NkBp	M17nOWROW09?	NHrzdopKSzVyPUGwJO69VQ>?	NXvGUWVjOjN6NESwN\|g>
NCI-N87	MmLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHLTeowyOCEQvF2=	M3zvflczKGh?	M1S5cWROW09?	MYHJR\|UxRTFyIN88US=>	NET3eFYzOzh2NECzPC=>
NCI-H146	NHLCSotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYTXOIRXOTBizszN	NYDtVVIyPzJiaB?=	MYLEUXNQ	MofkTWM2OD1zMDFOwG0>	M4j0U\|I{QDR2MEO4
NCI-H157	NUnIRlUyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVSxNEDPxE1?	M1PQWFczKGh?	MoPWSG1UVw>?	NYjhPVY5UUN3ME2xNEDPxE1?	NUHxfpNOOjN6NESwN\|g>
NCI-H187	M2XOb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVnZTWNQOTBizszN	M4PEb\|czKGh?	MlHFSG1UVw>?	NF;1TI9KSzVyPUGwJO69VQ>?	MXyyN\|g1PDB\|OB?=
NCI-H209	MmDVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGnGUW4yOCEQvF2=	Mmf5O\|IhcA>?	MnfrSG1UVw>?	MlywTWM2OD1zMDFOwG0>	Mly5NlM5PDRyM{i=
NCI-H226	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYnre3BGOTBizszN	M13iTlczKGh?	M4Xle2ROW09?	NEHQR4ZKSzVyPUGwJO69VQ>?	NWTjc3FVOjN6NESwN\|g>
NCI-H292	MkD5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUCxNEDPxE1?	MkjkO\|IhcA>?	NH;jSpRFVVOR	M2jVfGlEPTB;MUCg{txO	Mlq0NlM5PDRyM{i=
NCI-H322	M{eweWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV61SpF3OTBizszN	MXK3NkBp	M33pSGROW09?	MmLtTWM2OD1zMDFOwG0>	MXWyN\|g1PDB\|OB?=
NCI-H358	NUnPV\|F7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVjLeWN[OTBizszN	M1W1cVczKGh?	NIfKcW1FVVOR	MnLPTWM2OD1zMDFOwG0>	NH:x[pIzOzh2NECzPC=>
NCI-H520	NVfyOYZMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1jSPFExKM7:TR?=	Mo\kO\|IhcA>?	NWDpS4NPTE2VTx?=	NEnhXmZKSzVyPUGwJO69VQ>?	M1O0VVI{QDR2MEO4
NCI-H526	M4PhZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mlr5NVAh\|ryP	NX;wc3JjPzJiaB?=	M4j2dGROW09?	M3q2S2lEPTB;MUCg{txO	MUmyN\|g1PDB\|OB?=
NCI-H630	NXrFNWVnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIfmZZcyOCEQvF2=	MYC3NkBp	NF7Yd3RFVVOR	NYDsd41IUUN3ME2xNEDPxE1?	NF\PTZUzOzh2NECzPC=>
NCI-H661	M1i2bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWCxNEDPxE1?	MXK3NkBp	MUDEUXNQ	MV\JR\|UxRTFyIN88US=>	MWqyN\|g1PDB\|OB?=
NCI-H716	NIfpN2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWDOVHl{OTBizszN	NEHiTlE4OiCq	MlG2SG1UVw>?	M3jlSWlEPTB;MUCg{txO	NUPJ[FJ3OjN6NESwN\|g>
NCI-H1563	Mnu0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVrtUXU5OTBizszN	MUO3NkBp	MnTxSG1UVw>?	MVzJR\|UxRTFyIN88US=>	NH[yUZkzOzh2NECzPC=>
NCI-H1792	M2fYVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mnn0NVAh\|ryP	NHW3OWI4OiCq	MV3EUXNQ	M1fsZmlEPTB;MUCg{txO	M3nI[lI{QDR2MEO4
NCI-H2030	NGLzVoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1;TWFExKM7:TR?=	NGjwSoQ4OiCq	NVrCRZMxTE2VTx?=	MVHJR\|UxRTFyIN88US=>	MnLmNlM5PDRyM{i=
NCI-H2052	M3LPemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mmj1NVAh\|ryP	Mn;0O\|IhcA>?	NFz6SHFFVVOR	MlfDTWM2OD1zMDFOwG0>	NWCxfGVwOjN6NESwN\|g>
NCI-H2122	MmW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmXZNVAh\|ryP	Ml7yO\|IhcA>?	NX[yeGxJTE2VTx?=	M4\5SWlEPTB;MUCg{txO	M2TpNlI{QDR2MEO4
NCI-H2228	M1Tl[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFTXV5gyOCEQvF2=	MYS3NkBp	NUTDXZVrTE2VTx?=	M3jTSGlEPTB;MUCg{txO	NFraO\|AzOzh2NECzPC=>
OE-19	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmHSNVAh\|ryP	NXzGd25GPzJiaB?=	M17odWROW09?	NIHDOoFKSzVyPUGwJO69VQ>?	NH3XToYzOzh2NECzPC=>
OE-21	NGjIUpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlLpNVAh\|ryP	MoS4O\|IhcA>?	NWHNb\|czTE2VTx?=	NWW3bI5MUUN3ME2xNEDPxE1?	MoLUNlM5PDRyM{i=
OE-33	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnzlNVAh\|ryP	NIfUOpk4OiCq	MYLEUXNQ	MWPJR\|UxRTFyIN88US=>	NFGxflUzOzh2NECzPC=>
OVCAR-3	NGi5VG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXTxbXNmOTBizszN	Mn\4O\|IhcA>?	MkLOSG1UVw>?	NWLtXXZXUUN3ME2xNEDPxE1?	M2DXbVI{QDR2MEO4
OVCAR-4	M2Ha[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWOxNEDPxE1?	MWK3NkBp	MXfEUXNQ	NXvFS4d{UUN3ME2xNEDPxE1?	NXjmO2VSOjN6NESwN\|g>
OVCAR-5	MmrSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NI\x[2kyOCEQvF2=	MoXBO\|IhcA>?	MXLEUXNQ	MXjJR\|UxRTFyIN88US=>	M1ftTlI{QDR2MEO4
P3HR-1	Mn2yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4DWUVExKM7:TR?=	MnHEO\|IhcA>?	M3HoWWROW09?	MlT4TWM2OD1zMDFOwG0>	NGWwPVMzOzh2NECzPC=>
PC-3	M{S1Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVmxNEDPxE1?	MWO3NkBp	NED0XJZFVVOR	MoLZTWM2OD1zMDFOwG0>	NFzle3AzOzh2NECzPC=>
Raji	NHHlfIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoewNVAh\|ryP	NICw[\|Y4OiCq	NVzod\|NFTE2VTx?=	MUXJR\|UxRTFyIN88US=>	M2LpNFI{QDR2MEO4
RD	MnP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHTNfHAyOCEQvF2=	MnniO\|IhcA>?	MWfEUXNQ	M33OZWlEPTB;MUCg{txO	M3X2bVI{QDR2MEO4
RD-ES	Moq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkXmNVAh\|ryP	NXqwS5JIPzJiaB?=	NV;qRY9jTE2VTx?=	MoHsTWM2OD1zMDFOwG0>	MUGyN\|g1PDB\|OB?=
RL	NIX0VFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHmxVXYyOCEQvF2=	NWnxVJVsPzJiaB?=	NXzvendkTE2VTx?=	NFTIWm5KSzVyPUGwJO69VQ>?	MnnWNlM5PDRyM{i=
SaOS2	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV3RUWxNOTBizszN	NHjGSHA4OiCq	NFPWVIFFVVOR	Mlr1TWM2OD1zMDFOwG0>	NIXObXozOzh2NECzPC=>
SCC-9	NE\IfHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmS1NVAh\|ryP	NXS1fG1JPzJiaB?=	NUnxPIx4TE2VTx?=	MXPJR\|UxRTFyIN88US=>	M2HKb\|I{QDR2MEO4
SCC-12	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUT0SXJUOTBizszN	MlzzO\|IhcA>?	M2mwZWROW09?	NE[0[2dKSzVyPUGwJO69VQ>?	MVSyN\|g1PDB\|OB?=
SCC-13	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkTXNVAh\|ryP	MV23NkBp	Ml3ZSG1UVw>?	NXy3dFJbUUN3ME2xNEDPxE1?	NFn6XpEzOzh2NECzPC=>
SCC-15	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX6xNEDPxE1?	MWK3NkBp	NWPT[INYTE2VTx?=	MlnnTWM2OD1zMDFOwG0>	NWrCXow5OjN6NESwN\|g>
SCC-25	Mmj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGLBSFgyOCEQvF2=	NH\PRVU4OiCq	NEe5bJJFVVOR	NEH4VlJKSzVyPUGwJO69VQ>?	M3PmdlI{QDR2MEO4
SCLC-3	NYW2U5ppT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEK1cHMyOCEQvF2=	Mk\QO\|IhcA>?	NFf5WG9FVVOR	MWjJR\|UxRTFyIN88US=>	M37DUlI{QDR2MEO4
SF-268	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIftO\|IyOCEQvF2=	MXW3NkBp	M3vtXmROW09?	M2LNfWlEPTB;MUCg{txO	NIDQWpozOzh2NECzPC=>
SF-295	NYX4Wo1FT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGLzNGwyOCEQvF2=	MoLYO\|IhcA>?	NUDzSVV[TE2VTx?=	MUTJR\|UxRTFyIN88US=>	Mne2NlM5PDRyM{i=
SJRH30	MlOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXfWZnpmOTBizszN	NFjUR2Y4OiCq	MnziSG1UVw>?	NXvUWHlSUUN3ME2xNEDPxE1?	NYG5UGlmOjN6NESwN\|g>
SK-BR-3	Mlj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M13scVExKM7:TR?=	MmjrO\|IhcA>?	M4f1R2ROW09?	MXLJR\|UxRTFyIN88US=>	MWKyN\|g1PDB\|OB?=
SK-LMS-1	NID0UGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3jFNlExKM7:TR?=	NF3mNHo4OiCq	NVTpUpBRTE2VTx?=	Moi0TWM2OD1zMDFOwG0>	NHqwNlIzOzh2NECzPC=>
SK-N-DZ	NHfHWXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mnr5NVAh\|ryP	NEnCT\|Q4OiCq	M1WzeGROW09?	NX30OIRCUUN3ME2xNEDPxE1?	MkO4NlM5PDRyM{i=
SK-N-F1	NYq4dJNwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEjBVG4yOCEQvF2=	Mor0O\|IhcA>?	NXTPe4NCTE2VTx?=	NGPmR2VKSzVyPUGwJO69VQ>?	MnjNNlM5PDRyM{i=
SKOV-3	NInaemNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{joUlExKM7:TR?=	NGHZNXo4OiCq	MXTEUXNQ	MnLyTWM2OD1zMDFOwG0>	MViyN\|g1PDB\|OB?=
SK-UT-1	NHHYbYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mo\ENVAh\|ryP	NYrRT\|JMPzJiaB?=	NVXmV4VkTE2VTx?=	MYDJR\|UxRTFyIN88US=>	NFOzfIEzOzh2NECzPC=>
SN12C	NXy2S5B{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3LKV\|ExKM7:TR?=	M2rnPVczKGh?	NV\S[4xMTE2VTx?=	NUXCO21{UUN3ME2xNEDPxE1?	MkLXNlM5PDRyM{i=
SNB-19	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2nMdVExKM7:TR?=	NV32SmpWPzJiaB?=	MnHMSG1UVw>?	MVXJR\|UxRTFyIN88US=>	MUOyN\|g1PDB\|OB?=
SNU-5	Mn\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4fWN\|ExKM7:TR?=	NYfiWFJSPzJiaB?=	NGrne29FVVOR	NVTDW\|NNUUN3ME2xNEDPxE1?	MXKyN\|g1PDB\|OB?=
SNU-16	NEG4[Y1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVuxNEDPxE1?	MnK4O\|IhcA>?	NXjRfopGTE2VTx?=	MmT3TWM2OD1zMDFOwG0>	NF;iR\|MzOzh2NECzPC=>
SNU-398	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnzNNVAh\|ryP	NI\obHY4OiCq	Mn;PSG1UVw>?	MnrFTWM2OD1zMDFOwG0>	NHTvXoozOzh2NECzPC=>
SNU-449	NH20[mNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4HwOVExKM7:TR?=	M3\3dVczKGh?	MXTEUXNQ	M3XCe2lEPTB;MUCg{txO	MYOyN\|g1PDB\|OB?=
SR	MofNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MojXNVAh\|ryP	MUK3NkBp	NXWw[XR6TE2VTx?=	MmHITWM2OD1zMDFOwG0>	M13Xe\|I{QDR2MEO4
ST486	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUfkOJdUOTBizszN	NFnheIw4OiCq	M3jSfGROW09?	NYfpbI1WUUN3ME2xNEDPxE1?	Mn3GNlM5PDRyM{i=
SW579	NHTCNW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MliwNVAh\|ryP	Ml7qO\|IhcA>?	NVzyeZd5TE2VTx?=	NXPIXoZiUUN3ME2xNEDPxE1?	MWiyN\|g1PDB\|OB?=
SW684	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3PvWlExKM7:TR?=	M2jjb\|czKGh?	MWTEUXNQ	NWrmU5RoUUN3ME2xNEDPxE1?	MYOyN\|g1PDB\|OB?=
SW-780	MmW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIH1bHYyOCEQvF2=	MVO3NkBp	NFjXPYZFVVOR	NVW0UYV[UUN3ME2xNEDPxE1?	NEK4cGkzOzh2NECzPC=>
SW900	MmTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn3GNVAh\|ryP	MofDO\|IhcA>?	MXzEUXNQ	MlnITWM2OD1zMDFOwG0>	NV2xVop{OjN6NESwN\|g>
SW1088	NIXKU3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3XoRVExKM7:TR?=	M2nCdlczKGh?	M2OyXmROW09?	M3HESGlEPTB;MUCg{txO	NV\UN2FoOjN6NESwN\|g>
SW1463	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGjMOXUyOCEQvF2=	NGTob3Y4OiCq	M3rvPGROW09?	NUnFNFZRUUN3ME2xNEDPxE1?	NFrNTWszOzh2NECzPC=>
SW1990	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml7ZNVAh\|ryP	MXm3NkBp	NYfk[\|hFTE2VTx?=	MljPTWM2OD1zMDFOwG0>	NUX2WldXOjN6NESwN\|g>
T47D	NIP6Wm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWHsdI9vOTBizszN	NYq1R3M3PzJiaB?=	NGPtVopFVVOR	NEKxXnhKSzVyPUGwJO69VQ>?	MVKyN\|g1PDB\|OB?=
TE381.T	M{PvSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3[yUVExKM7:TR?=	MVy3NkBp	NGTXOIhFVVOR	M1jrO2lEPTB;MUCg{txO	NVXKVGE2OjN6NESwN\|g>
TK-10	NWnHN4RRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVTtfnQ6OTBizszN	MYi3NkBp	MWLEUXNQ	NUW1WnVIUUN3ME2xNEDPxE1?	MWGyN\|g1PDB\|OB?=
U2OS	NVfQbXA1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUfQTnh4OTBizszN	Mk\NO\|IhcA>?	NX7uNXVOTE2VTx?=	NYXncHYzUUN3ME2xNEDPxE1?	M{HMcFI{QDR2MEO4
U251	NGTnSlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmXNNVAh\|ryP	MnTZO\|IhcA>?	NEnBe4NFVVOR	Mn3zTWM2OD1zMDFOwG0>	MXGyN\|g1PDB\|OB?=
UACC-812	NVjE[VhRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV\CZlZbOTBizszN	MlWyO\|IhcA>?	NFzJUJFFVVOR	MXfJR\|UxRTFyIN88US=>	NWLWW5FlOjN6NESwN\|g>
YAPC	NVTvfZM4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnTVNVAh\|ryP	NUO1b5EzPzJiaB?=	NFvpfnFFVVOR	NGezWm1KSzVyPUGwJO69VQ>?	M3O5NlI{QDR2MEO4
ZR-75-1	NHrCN3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGDISpcyOCEQvF2=	MWi3NkBp	NH3EUnVFVVOR	MVLJR\|UxRTFyIN88US=>	MlPENlM5PDRyM{i=
A375	MVvGeY5kfGmxbjDhd5NigQ>?	M1ToflEvOiEQvF2=	NETK[IU1KGh?	NXzvUGs5TE2VTx?=	M2GwNmlvcGmkaYTpc44hd2ZicHjvd5Bpd3K7bHH0bY9vKG:oIF3FT{whTVKNLDDhcoQhWz[S	NH64fFIzOjN6OUS3NS=>
YUSIT1	Mki3SpVv[3Srb36gZZN{[Xl?			NHKyXG5FVVOR	NGD4SVRz\WS3Y3XkJJNmdnOrdHn2bZR6KHerdHigTWM2OCB-IECuOUDPxE1?	MoH1NlI{QDl2N{G=
MeWo	NELneZRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			M1LCXmROW09?	M3G3cmlEPTBiPTC5PFchdk1?	M{fFbVI3ODF6NUK0
WiDr	NXf1WlZGT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			M1v3O2ROW09?	M4LHOGlEPTBiPTC3OkBvVQ>?	MmnwNlYxOTh3MkS=
Colo-205	M1GzdWZ2dmO2aX;uJIF{e2G7	M3TMUFEh\|ryP	NHTFXIk1KGR?	MUPEUXNQ	MX3JcoR2[2WmIHGgbIlocGy7IHPvcZBiemGkbHWgZ49ueGGldHnvckBxcGWwb4T5dIU>	NWH1SWhLOjV\|OEGxOVI>
RBW-1	NFPDZ5hHfW6ldHnvckBie3OjeR?=	M2[wUVEh\|ryP		NIq5copFVVOR	MWjOc{Bz\WS3Y4Tpc44hd2ZiTXXrJFEwOiCyaH;zdIhwenmuYYTpc44>	NVfFZY5iOjR6OEW2PVA>
RBO-1	M1nNZmZ2dmO2aX;uJIF{e2G7	NUHNU2FZOSEQvF2=		M{nyPGROW09?	MYDJcohq[mm2aX;uJI9nKE2nazCxM\|IheGixc4Doc5J6dGG2aX;u	NFPNTnczPDh6NU[5NC=>
RBO-2	NX3JZ4hvTnWwY4Tpc44h[XO\|YYm=	Mn6wNUDPxE1?		NXnvOY0{TE2VTx?=	MWnJcohq[mm2aX;uJI9nKCCPZXugNU8zKHCqb4PwbI9zgWyjdHnvci=>	M17lcVI1QDh3Nkmw
RBOW	MmnuSpVv[3Srb36gZZN{[Xl?	NWnubFhGOSEQvF2=		MoHzSG1UVw>?	NVnOdoNRUW6qaXLpeIlwdiCxZjCgUYVsKDFxMjDwbI9{eGixconsZZRqd25?	MlnLNlQ5QDV4OUC=
M257	NHK1cYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIj6WoUyODBibl2=	MXi3NkBp		NIHZWIVFd2W\|IH7veEBqdmirYnn0JJBzd2yrZnXyZZRqd25ib3[gUVI2PyClZXzsJIhiemKxdYLpcochf2muZDD0fZBmKEKUQV[=	M1rGOlI{OzF5NES2
LCP	NWnlfog1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWOxNFAhdk1?	MmG1O\|IhcA>?		M4nhc2lvcGmkaYTpc44hd2ZicILvcIln\XKjdHnvckBw\iCOQ2CgZ4VtdCCqYYLic5VzcW6pIFLSRWYhXjZyMGKgcZV1[W62YYTpc44>	M2Cy[VI{OzF5NES2
WM266	NGW3R45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEH6XncyODBibl2=	NULLXYFsPzJiaB?=		NGPpVnpKdmirYnn0bY9vKG:oIIDyc4xq\mW{YYTpc44hd2ZiV12yOlYh[2WubDDoZZJjd3W{aX7nJGJTSUZiVk[wNWQhdXW2YX70ZZRqd25?	M4TvblI{OzF5NES2
M257	NYLld4lpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEjWS5gyODBibl2=	NUD0[JVPPzJiaB?=		M4TJTmRw\XNibn;0JIlvcGmkaYSgSXJMOS1{IIDoc5NxcG:{eXzheIlwdiCrbjDNNlU4KGOnbHygbIFz[m:3cnnu[{B4cWymIIT5dIUhSlKDRh?=	MnSxNlM{OTd2NE[=
LCP	NFLtWJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4jEO\|ExOCCwTR?=	NHXBRYw4OiCq		MYjJcohq[mm2IFXST\|EuOiCyaH;zdIhwenmuYYTpc44hcW5iTFPQJINmdGxiaHHyZo92emmwZzDCVmFHKFZ4MEDSJI12fGGwdHH0bY9v	MXuyN\|MyPzR2Nh?=
WM266	MlPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MknxNVAxKG6P	NEXZd4o4OiCq		NGjYZmdKdmirYnn0JGVTUzFvMjDwbI9{eGixconsZZRqd25iaX6gW20zPjZiY3XscEBp[XKkb4XybY5oKEKUQV[gWlYxOERibYX0ZY51[XSrb36=	NVzjO3p[OjN\|MUe0OFY>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pMEK / pERK / ERK; PubMed: 31158244 PLoS One Cell lines as shown were treated with dabrafenib, over a dose range, for 1 hour. UT = untransfected. Expression and/or phosphorylation of the indicated proteins were assessed by immunoblot. p-S6 / p-AKT308 / p-AKT473; PubMed: 24735930 Mol Cancer Western blot analysis of phosphorylated proteins in MAPK and the PI3K-AKT pathway after 24 hours exposure to increasing concentrations of dabrafenib. β-catenin; PubMed: 29167314 Mol Cancer Ther HT-29 cells were treated with BRAF inhibitors Dabrafenib (2 μM), GDC-0879 (4 μM) or Vemurafenib (2 μM) for indicated times. The whole cell lysates were used for western blot with indicated antibodies.	31158244 24735930 29167314
Growth inhibition assay	IC50; PubMed: 24735930 Mol Cancer A panel of 23 BRAF(V600) mutant human melanoma cell lines was treated with serial dilutions (1-10,000 nM) of dabrafenib (A) for 72-120 hours to assess cell viability. The bars represent the average IC50 value of two or more independent experiments in duplicates and the error bars represent the SEM.	24735930

In vivo

Dabrafenib (orally administrated) inhibits the growth of B-RafV600E mutant melanoma (A375P) and colon cancer (Colo205) human tumor xenografts, growing subcutaneously in immuno-compromised mice. ^[1]

Protocol

References

Solubility (25°C)

In vitro	DMSO	30 mg/mL (57.74 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+45% PEG 300+2% Tween 80+ddH2O For best results, use promptly after mixing.	5 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Dabrafenib (GSK2118436) SDF

Molecular Weight	519.56
Formula	C₂₃H₂₀F₃N₅O₂S₂
CAS No.	1195765-45-7
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(F)C(=CC=C3)N[S](=O)(=O)C4=C(F)C=CC=C4F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-05-15)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04059224	Recruiting	Drug: Trametinib\|Drug: Dabrafenib	Stage IV Melanoma\|Stage III Melanoma	Universitair Ziekenhuis Brussel	January 28 2019	Phase 2
NCT03668431	Recruiting	Drug: Dabrafenib\|Drug: Trametinib\|Drug: PDR001	Metastatic Colorectal Cancer	Massachusetts General Hospital\|Novartis\|Stand Up To Cancer	October 15 2018	Phase 2
NCT03553329	Completed	Drug: dabrafenib	Unresecable Stage IIIc or IV Melanoma	Poitiers University Hospital	June 2 2018	--
NCT03593993	Recruiting	Procedure: Surgical Cohort	Glioma\|BRAF V600E\|Pleomorphic Xantho-Astrocytoma\|Glioblastoma	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|Musella Foundation	May 19 2018	--
NCT03340506	Recruiting	Drug: dabrafenib\|Drug: trametinib	Melanoma\|Non Small Cell Lung Cancer\|Solid Tumor\|Rare Cancers\|High Grade Glioma	Novartis Pharmaceuticals\|Novartis	December 28 2017	Phase 4

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Raf Signaling Pathway Map

Raf Inhibitors with Unique Features

Pan Raf Inhibitor

AZ 628 : Pan-Raf inhibitor, BRAF, IC50=105 nM; BRAFV600E, IC50=34 nM; c-Raf-1, IC50=29 nM.
FDA-approved Raf Inhibitor

Sorafenib Tosylate : Approved by FDA for advanced renal cancer。
Newest Raf Inhibitor

TAK-632 ^New : Potent pan-Raf inhibitor with IC50 of 8.3 nM and 1.4 nM for B-Raf(wt) and C-Raf, respectively, showing less or no inhibition against other tested kinases.

Related Raf Products

LY3009120 ^New

LY03009120 is a potent pan-Raf inhibitor with IC50 of 44 nM, 31-47 nM, and 42 nM for A-raf, B-Raf, and C-Raf in A375 cells, respectively. Phase 1.
Ravoxertinib (GDC-0994) ^New

GDC-0994 is a potent, orally available and highly selective ERK1/2 inhibitor with IC50 of 1.1 nM and 0.3 nM, respectively. Phase 1.
Ulixertinib (BVD-523) ^New

Ulixertinib (BVD-523, VRT752271) is a potent and reversible ERK1/ERK2 inhibitor with IC50 of <0.3 nM for ERK2. Phase 1.
Vemurafenib (PLX4032)

Vemurafenib (PLX4032, RG7204) is a novel and potent inhibitor of B-Raf^V600E with IC50 of 31 nM in cell-free assay. 10-fold selective for B-Raf^V600E over wild-type B-Raf in enzymatic assays and the cellular selectivity can exceed 100-fold. Vemurafenib (PLX4032, RG7204) induces autophagy.

Features:A novel and potent inhibitor of the B-RAF^V600E oncoprotein.
Sorafenib

Sorafenib is a multikinase inhibitor of Raf-1 and B-Raf with IC50 of 6 nM and 22 nM in cell-free assays, respectively. Sorafenib inhibits VEGFR-2, VEGFR-3, PDGFR-β, Flt-3 and c-KIT with IC50 of 90 nM, 20 nM, 57 nM, 59 nM and 68 nM, respectively. Sorafenib induces autophagy and apoptosis and activates ferroptosis with anti-tumor activity.
Sorafenib Tosylate

Sorafenib Tosylate is a multikinase inhibitor of Raf-1 and B-Raf with IC50 of 6 nM and 22 nM in cell-free assays, respectively. Sorafenib Tosylate inhibits VEGFR-2, VEGFR-3, PDGFR-β, Flt-3 and c-KIT with IC50 of 90 nM, 20 nM, 57 nM, 59 nM and 68 nM, respectively. Sorafenib Tosylate induces autophagy and apoptosis and activates ferroptosis with anti-tumor activity.
PLX-4720

PLX4720 is a potent and selective inhibitor of B-Raf^V600E with IC50 of 13 nM in a cell-free assay, equally potent to c-Raf-1(Y340D and Y341D mutations), 10-fold selectivity for B-RafV600E than wild-type B-Raf.
TAK-632

TAK-632 is a potent pan-Raf inhibitor with IC50 of 8.3 nM and 1.4 nM for B-Raf(wt) and C-Raf in cell-free assays, respectively, showing less or no inhibition against other tested kinases.
GDC-0879

GDC-0879 is a novel, potent, and selective B-Raf inhibitor with IC50 of 0.13 nM in A375 and Colo205 cells with activity against c-Raf as well; no inhibition known to other protein kinases.
GW5074

GW5074 is a potent and selective c-Raf inhibitor with IC50 of 9 nM, no effect on the activities of JNK1/2/3, MEK1, MKK6/7, CDK1/2, c-Src, p38 MAP, VEGFR2 or c-Fms is noted.

Choose Your Country or Region

By Signaling Pathways

By product type

Dabrafenib (GSK2118436)